

AUG 15 2005

ultra
RAD**510(k) Summary of Safety and Effectiveness**

This 510(k) summary of safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990.

Date Prepared:

June 27, 2005

Submitter's Information: 21 CFR 807.92(a)(1)

Tom Goliash, President / CEO
 UltraRAD Corporation
 801 West Bay Drive, Suite 424
 Largo, FL 33770
 Tel: 800-719-9379
 Email: tgoliash@ultraradcorp.com

Trade Name, Common Name and Classification: 21 CFR 807.92(a)(2)

Trade name - UltraPACS™ by UltraRAD Corporation
 Common name - Picture, Archive, and Communications System
 Classification name - system, image processing, radiological (21 CFR 880.2050, Product Code LLZ)

Predicate Device: 21 CFR 807.92(a)(3)

Device Classification Name	System, Image Processing, Radiological	System, Image Processing, Radiological
Regulation Number	892.2050	892.2050
510(k) Number	K042311	K041500
Device Name	PACSPartner	StarPACS Ortho
Applicant	Medical Standard Co. Ltd.	Infinitt Co. Ltd.
Product Code	LLZ	LLZ
Decision Date	09/09/2004	06/21/04

Device Description: 21 CFR 807.92(a)(4)

UltraPACS™ makes possible the capturing, storage, distribution, and networking of medical images at distributed locations. In cases where DICOM images are not directly available to UltraPACS™, the system can acquire medical images using a DICOM gateway, which generates DICOM-type files. For example, film digitizers obtain images from old film and convert them to meet DICOM standards and stored in an archive. Stored files are transmitted using a network and can be viewed or manipulated from an imaging workstation. The orthopedic application is intended to assist orthopedic surgeons when doing preoperative planning and post-operative follow-up. The orthopedic application of the device is used to overlay prosthesis templates on radiological images, tools for repositioning the templates, and tools for measurements in the images.

Indications for Use: 21 CFR 807.92(a)(5)

UltraPACS™ system is device that receives digital images and data from various sources (e.g. CT scanners, MR scanners, ultrasound systems, R/F Units, computed & direct radiographic devices, secondary capture devices, scanners, imaging gateways or other

imaging sources). Images and data can be stored, communicated, processed and displayed within the system and or across computer networks at distributed locations. The device can also assist orthopedic surgeons when doing preoperative planning and post-operative follow-up.

Options make possible reading (including mammography), telecommunications, fast demonstration; etc.; and teleconferencing.

Lossy compressed or digitized screen film mammographic images must not be reviewed for primary image interpretations. Only FFDM manufacturer processed images in DICOM "For Presentation" format can be displayed for primary interpretation. Mammographic images must only be interpreted using a FDA approved monitor that offers at least 5Mpixel resolutions and other technical specifications reviewed and accepted by the FDA.

Typical users of this system are trained professionals, physicians, nurses, and technicians.

Technological Characteristics: 21 CFR 807 92(a)(6)

UltraPACS™ is a Picture Archiving and Communications device that handles digital medical images. The device does not contact the patient, nor does it control any life sustaining devices. A physician, providing ample opportunity for competent human intervention interprets images and information being displayed and printed.

Conclusion: 21 CFR 807 92(b)(1)

The 510(k) Pre-Market Notification for UltraPACS™ contains adequate information and data to enable FDA - CDRH to determine substantial equivalence to the predicate device.

UltraPACS™ has been and will be manufactured in accordance with the voluntary standards listed in the enclosed voluntary standard survey. The submission contains the results of a hazard analysis and the "Level of Concern for potential hazards has been classified as "Minor".



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

AUG 15 2005

UltraRAD Corporation
% Mr. Carl Alletto
Official Correspondent
1600 Manchester Way
CORINTH TX 76210

Re: K051813
Trade/Device Name: UltraPACSTTM
Regulation Number: 21 CFR 892.2050
Regulation Name: Picture archiving and
communications system
Regulatory Class: II
Product Code: LLZ
Dated: June 27, 2005
Received: July 13, 2005

Dear Mr. Alletto:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

21 CFR 876.xxxx	(Gastroenterology/Renal/Urology)	240-276-0115
21 CFR 884.xxxx	(Obstetrics/Gynecology)	240-276-0115
21 CFR 892.xxxx	(Radiology)	240-276-0120
Other		240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Nancy C. Brogdon
Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

(Indications for Use Form)510(k) Number: K051813Device Name:
UltraPACS™

Indications for Use:

UltraPACS™ system is device that receives digital images and data from various sources (e.g. CT scanners, MR scanners, ultrasound systems, R/F Units, computed & direct radiographic devices, secondary capture devices, scanners, imaging gateways or other imaging sources). Images and data can be stored, communicated, processed and displayed within the system and or across computer networks at distributed locations. The device can also assists orthopedic surgeons when doing preoperative planning and post-operative follow-up.

Options make possible reading (including mammography), telecommunications; fast demonstration; etc.; and teleconferencing.

Lossy compressed or digitized screen film mammographic images must not be reviewed for primary image interpretations. Only FFDM manufacturer processed images in DICOM "For Presentation" format can be displayed for primary interpretation. Mammographic images must only be interpreted using a FDA approved monitor that offers at least 5Mpixel resolutions and other technical specifications reviewed and accepted by the FDA.

Typical users of this system are trained professionals, physicians, nurses, and technicians.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓ AND/OR Over-The-Counter Use _____
(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

David B. Begum
(Division Sign-Off)Division of Reproductive, Abdominal,
and Radiological Devices510(k) Number K051813